TruNativ raises $30M from OrbiMed to scale clean-label nutrition

Key Takeaways

• TruNativ secured $30 million from OrbiMed Advisors, combining primary investment with secondary share sales from early investors
• The company plans to scale distribution, expand products, and launch an R&D center in Mumbai
• TruNativ projects Rs 200 crore revenue for FY27 after closing FY26 at Rs 130 crore

TruNativ, a Mumbai-based clean-label nutrition company, has raised $30 million from healthcare-focused investor OrbiMed Advisors LLC. The round includes both fresh capital and secondary share sales by early backers. The company will use the funds to expand distribution, widen its product lineup, and build a dedicated R&D center in Mumbai.

Founded in 2019 by Pranav and Mamta Malhotra, TruNativ sells sugar alternatives, protein supplements, gut health products, and general wellness items. The brand positions itself as "clean-label," meaning products without artificial additives or opaque ingredient lists.

"After the pandemic, people have become aware of their nutritional needs, but are struggling to meet them," CEO Pranav Malhotra said. "So our entire focus has been to integrate nutrition into people's daily lives instead of forcing them to do a hard shift."

Where will TruNativ spend the $30 million?

Three priorities dominate the spending plan. First, TruNativ will scale its distribution network to reach more consumers directly. Second, it will grow its B2B2C ingredients business, which supplies other consumer brands in India. Third, the company will establish an innovation and R&D center in Mumbai.

On the R&D front, Malhotra acknowledged that TruNativ imports its whey protein like most competitors. The differentiator, he said, lies in proprietary flavor formulations and customized supplement blends. The new center will focus on developing products in protein, gut health, and sweetener categories.

Dr. Sunny Sharma, senior managing director at OrbiMed Asia, framed the investment around health outcomes. "We share Pranav's passion for improving nutrition nationwide and enhancing health outcomes through healthier dietary habits," Sharma said.

Financial trajectory and competitive landscape

TruNativ closed FY26 with Rs 130 crore in revenue. Management expects to hit Rs 200 crore in FY27, a 54% year-over-year jump. That growth rate will test the company's ability to scale operations while maintaining product quality.

The competitive field is crowded. TruNativ faces OZiva (backed by HUL), Wellbeing Nutrition (owned by USV), and Plix (acquired by Marico). Emami bought a 19% stake in TruNativ back in 2022, signaling that legacy FMCG players see value in the clean-label segment.

The secondary share component of this round is notable. Some early investors sold their positions, which suggests confidence among new buyers like OrbiMed that TruNativ's best growth lies ahead. It also gives early backers liquidity without requiring an IPO or full exit.

Why clean-label nutrition is attracting capital now

The pandemic reshaped how Indians think about health. Supplement and wellness brands saw a demand spike that has not fully receded. Consumers now read labels more carefully and prefer products that promise transparency over synthetic formulations.

TruNativ's strategy of embedding nutrition into daily routines rather than marketing specialized regimens aligns with this shift. Sugar alternatives, for instance, let consumers swap out ingredients in their existing cooking rather than adopt unfamiliar supplements.

The B2B2C model adds a revenue stream that does not depend entirely on building consumer brand awareness. Supplying ingredients to other brands generates steadier margins and reduces customer acquisition costs.

What this signals for Indian wellness startups

OrbiMed's entry into TruNativ marks continued institutional interest in Indian health and wellness despite a broader funding slowdown. Healthcare-focused funds see nutrition as a natural extension of their thesis, especially when brands can demonstrate recurring revenue and defensible product differentiation.

For other D2C nutrition startups, the takeaway is clear: investors want to see paths to profitability, not just top-line growth. TruNativ's B2B2C play and secondary share sale suggest a maturing business model, not just another venture-backed brand spending heavily on Instagram ads.

Frequently Asked Questions

How much did TruNativ raise in this funding round?

TruNativ raised $30 million from OrbiMed Advisors LLC. The round included both primary investment and secondary share sales from early investors.

What products does TruNativ sell?

TruNativ sells clean-label nutrition products including sugar alternatives, protein supplements, gut health items, and general wellness products.

Who are TruNativ's main competitors?

TruNativ competes with OZiva (backed by HUL), Wellbeing Nutrition (owned by USV), and Plix (owned by Marico) in India's nutrition and wellness market.

What is TruNativ's revenue projection for FY27?

TruNativ expects to reach Rs 200 crore in revenue for FY27, up from Rs 130 crore in FY26.

What does clean-label mean in nutrition?

Clean-label refers to products made with transparent, recognizable ingredients without artificial additives, synthetic chemicals, or opaque formulations.

Source: Tech-Economic Times / ET